Articles tagged with Cancer Patients
Researchers found that probiotic bacteria Lactobacillus reuteri stimulates cancer-killing T cells by secreting indole-3-aldehyde, which activates a receptor in CD8 cells. A diet rich in tryptophan enhances the effect of immunotherapy on shrinking tumors and prolonging survival.
Researchers have identified a biomarker signature that can predict which patients with kidney cancer will respond well to immunotherapy. The signature is based on the number of immune cells in and around tumors, the amount of dead cancer tissue, and mutations to a tumor suppressor gene called PBRM1.
Enoblituzumab, a monoclonal antibody, is safe in men with aggressive prostate cancer and may induce clinical activity against cancer throughout the body. The drug targets B7-H3 protein overexpressed on prostate cancer cells, blocking immune system inhibition and triggering tumor cell destruction by activating immune cells.
A study published in Radiology found that ultrasound is an effective standalone diagnostic method for patients with focal breast complaints. The analysis showed that ultrasound alone led to accurate diagnosis in 90% of patients, with over 80% of complaints being benign findings.
A new study published in JNCCN identifies a targeted approach to improve end-of-life conversations for people with cancer. Researchers found that specially trained oncology infusion room nurses can increase the rate of advance care planning, leading to more supported decision-making.
A UNIGE team created customizable treatments by testing drugs on artificial tumors derived from patients' cancer tissue. The approach opens the way for optimized and tailored therapies against various cancers and diseases.
A study published in the journal Cancer found that long-term pancreatic cancer survivors have a robust immune response and enriched gut microbiome species, including Faecalibacterium prausnitzii. The research suggests that these bacterial species may promote immune response to pancreas cancer.
Researchers have shown lorlatinib to be safe and effective in treating high-risk neuroblastoma with ALK gene mutations. The targeted therapy has led to a major amendment in a phase 3 clinical trial, offering new hope for patients with this often lethal cancer.
The NRG Oncology combined trial results indicate that pathologic complete response (pCR) is associated with improved survival outcomes for patients with localized soft tissue sarcoma. pCR can be used as a prognostic factor for clinical outcomes in future STS research, with patients achieving higher overall and disease-free survival rates.
A phase 2 study found a 92% disease control rate with the combination of belzutifan and cabozantinib in pre-treated advanced kidney cancer patients. The treatment has a manageable safety profile, providing a potential alternative for patients experiencing disease progression on immunotherapy.
Researchers propose conjugating a cell-penetrating peptide to oxaliplatin to overcome chemotherapy resistance in colorectal cancer. The new approach reduces platinum accumulation in tumour microenvironment and healthy tissues.
A new study reveals that patients with blood cancers experience significant improvement in their reported well-being after receiving CAR T-cell therapy. The therapy not only improves physical symptoms but also anxiety and depression symptoms.
Researchers found that neutrophils can be pro- or anti-tumour depending on their surface markers, and those fighting tumours share cytotoxic power with neutrophils in bacterial infections. Blocking these anti-tumour neutrophils eliminates treatment benefits.
A clinical trial has established surgery as an effective treatment option for patients with early metastatic seminoma, a slow-growing form of testicular cancer. Surgery has been shown to offer better outcomes than traditional therapies like chemotherapy and radiation, with fewer long-term side effects.
Researchers at the University of Texas M. D. Anderson Cancer Center have developed a novel approach to administer intrathecal and intravenous immunotherapy to treat leptomeningeal disease (LMD) in melanoma patients, showing promising results in improving survival rates and quality of life for some patients.
A rapid genetic testing model identified pathogenic variants in 51 patients with advanced prostate cancer, leading to discussions of possible treatment changes for 22 patients. The streamlined approach detected actionable gene variants eligible for newer targeted therapies in nearly half of patients with these variants.
Researchers at Georgia Institute of Technology developed a synthetic tumor model to understand the impact of microenvironment on targeted therapies for Activated B Cell-like Diffuse Large B cell lymphoma. The model showed promise in demonstrating how combining therapeutics can overcome tumor resistance to inhibitors.
A new PET/CT scanner prototype has shown promising results in preclinical testing, offering higher resolution and accurate tumor assessment. The scanner aims to enhance treatment planning for head and neck cancers, which have a low five-year survival rate and high recurrence rate.
A large population study reveals that common cancer symptoms are pervasive across all types of cancer and sociodemographics, with higher symptom burdens among patients with lung, gastrointestinal, and gynecologic cancers. The study highlights the importance of prioritizing symptom management in patients who need or desire treatment.
Research outlines actionable steps to address longstanding health disparities in breast cancer screening and treatment options. Surgeons can drive change by maintaining awareness of existing disparities and providing additional resources to patients.
Researchers found that COVID-19 vaccination generates robust T cell responses in haematology patients, on par with healthy individuals. The study provides key insights for future immunisation strategies and shows that mRNA vaccines can elicit strong T cell immunity in patients with co-morbidities.
A new drug combination has doubled the expected time until cancer progression in heavily resistant head and neck cancer patients. The treatment, which includes a monoclonal antibody drug called ficlatuzumab, has shown an unusually high response rate of 38% in HPV-negative patients.
Scientists have engineered a unique strain of probiotic bacteria to over-express a metal transporter that binds and concentrates copper, facilitating the delivery of radionuclide therapy to cancer cells. This approach targets tumors without relying on specific receptors, making it potentially effective against treatment-resistant cancers.
A proactive patient education/recruitment program, administered with a nurse navigator, identified 37.3% more eligible patients for low-dose computed tomography (LDCT) screenings for lung cancer. The program led to a 42% increase in LDCT prescriptions among willing and eligible patients.
The NRG-GY018 trial found that pembrolizumab significantly improved progression-free survival outcomes in women with stage III-IV or recurrent endometrial cancer, particularly those with mismatch repair deficient tumors. The treatment also demonstrated improved overall survival and quality of life outcomes.
The ENGOT-EN6-NSGO/GOG-3031/RUBY trial reveals significant improvements in progression-free survival and overall survival for patients with primary advanced or recurrent endometrial cancer when treated with dostarlimab in combination with standard of care carboplatin/paclitaxel. The new treatment regimen offers a substantial increase i...
ENZAMET, a new drug combination, has shown significant improvement in survival rates for men with advanced prostate cancer. After five years, the treatment led to a 67% survival rate, compared to 57% for standard therapy.
A phase II trial investigating the combination of ribociclib and letrozole showed a response rate of 23%, progression-free survival of 19.1 months, and duration of response of 19.1 months in patients with recurrent low-grade serous ovarian cancer.
Women with locally advanced squamous cell carcinoma of the vulva who received gemcitabine concurrently with cisplatin and intensity-modulated radiation therapy exhibited increased rates of pathologic complete responses. The study found improved survival and response outcomes for this population, while minimizing toxicity.
The NRG-GY017 trial found that atezolizumab improved 2-year disease-free survival rates (79% vs. 59%) and pathologically complete or partial responses (69% vs. 40%) for patients with locally advanced cervical cancer. The study also showed a favorable immune response, including positive PD-L1 scoring and T-cell receptor clonal expansion.
Researchers developed an AI-based diagnostic screening system called DeepGlioma to analyze tumor specimens and detect genetic mutations rapidly. The system identified molecular subgroups with high accuracy and has the potential to improve access and speed of diagnosis for patients with deadly brain tumors.
Scientists have identified a new molecule that could help distinguish and treat patients with a specific subgroup of medulloblastoma, the most common malignant brain tumor in children. The discovery points to potential targeted therapies using a drug or drugs to block the molecule's activity.
Researchers identified high expression of glypican-1 in primary solid tumors, correlating with poor prognosis in various cancer types. Suppression of GPC1 attenuated cancer cell proliferation, suggesting its potential as a novel diagnostic tool and target for therapy.
Researchers found that physical activity can prevent cancer recurrence in stage III colon cancer patients by lowering the recurrence rate within the first year of treatment. This association persisted for approximately three years after surgery, suggesting a long-term survival benefit.
A new surgical therapy has proven effective in treating melanoma in the eye that has spread to the liver, with 40% of patients experiencing tumor shrinkage, and offers a promising alternative to current treatments.
A recent review article highlights the significant impact of cancer on Hispanic patients and their caregivers, citing communication barriers, financial difficulties, and sociocultural issues. The study estimates 126,000 new cancer cases diagnosed yearly in Hispanics, placing a substantial burden on family members and friends.
Researchers at Mayo Clinic have made significant progress in treating multiple myeloma using chimeric antigen receptor therapy (CAR-T cell therapy), which has shown a median progression-free survival of 13.3 months compared to 4.4 months for standard treatment regimens.
Researchers have found a new solution to combat resistant staphylococcus aureus infections, which can be difficult to treat. Endolysins, a newly developed enzyme, has been shown to kill both resistant and non-resistant staphylococcus aureus without the need for antibiotics.
A new method to cure HIV using umbilical cord blood stem cells has yielded long-term successful results for a middle-aged mixed-race woman with leukemia and HIV. The approach broadens the opportunities for people of diverse ancestry to attain cures.
A Phase II trial led by researchers from the University of Texas MD Anderson Cancer Center demonstrated that adding ipilimumab to a neoadjuvant combination of nivolumab plus platinum-based chemotherapy resulted in a major pathologic response in half of all treated patients with early-stage non-small cell lung cancer. The treatment also...
Researchers at Karolinska Institutet discovered an immune cell in women with pancreatic cancer that blocks the immune response, leading to poor survival. The study identifies a specific protein FPR2 as a potential therapeutic target for immunotherapy in women.
Researchers found a strong association between high levels of telomerase reverse transcriptase (TERT) expression and an elevated immune response in patients with head and neck squamous cell carcinoma. This link suggests a potential new target for cancer immunotherapies, which may lead to improved outcomes for patients.
A new review paper suggests that selective protection of normal cells from chemotherapy could increase the therapeutic window and improve outcomes for cancer patients. The authors propose using antagonistic drug combinations to kill drug-resistant cancer cells, reducing side effects and improving quality of life.
A systematic review of 33 randomized controlled trials found that yoga improved gait speed and lower extremity strength in inactive older people. However, it did not offer a benefit for frailty markers compared to exercise or tai chi.
The ProtecT trial found that active monitoring of prostate cancer has the same high survival rates after 15 years as radiotherapy or surgery. Men on active monitoring were more likely to see their cancer progress, but this didn't reduce their likelihood of survival.
A recent study published in JNCCN found that the lack of genomic research for people with African ancestry is hindering efforts to reduce disparities in prostate cancer outcomes. The researchers evaluated molecular genetic results for 113 Black South African men diagnosed with advanced prostate cancer, identifying 17 pathogenic and pot...
Researchers have developed a new imaging approach to diagnose advanced non-alcoholic fatty liver disease (NASH). The enzyme-sensitive nanoprobe emits signals that can be detected by MRI techniques, providing more accurate and sensitive data for diagnosis. This breakthrough aims to improve the treatment outcomes of NASH patients.
Researchers have identified a new method to predict which sarcoma patients will benefit from a potential new treatment. By inhibiting the plk1 gene, they were able to target and slow down the growth of sarcoma cells. This breakthrough could lead to improved treatment options for sickest sarcoma patients in 5-10 years.
Researchers developed a blood test to detect residual leukemia in AML patients before bone marrow transplant, showing that those with persistent mutations had higher risks of relapse and lower survival rates. The study supports ongoing research on precision medicine and personalized post-transplant care.
Researchers found that FABP5 is linked to more aggressive disease and poorer survival in multiple myeloma. Patients with higher FABP5 expression had significantly shorter time to disease progression and overall survival.
Researchers have identified a biomarker that can select breast cancer patients who may benefit from denosumab treatment. The study found that tumors with high RANK protein expression are associated with poor prognosis and response to chemotherapy, suggesting that denosumab may be effective in hormone-receptor negative tumors.
New research analyzed data on 8,007 patients with stage I–III breast cancer to predict recurrence risk based on cancer stage and receptor status. Patients with certain receptor combinations had higher or lower risks of recurrence at different stages.
Lung cancer patients with moderate to severe depression are 2-3 times more likely to have inflammation levels that predict poor survival rates, according to a new study. The results suggest depression may be as important or even more important than other factors in determining lung cancer outcomes.
A team of scientists has developed a novel, implantable drug delivery system that can be controlled by external light sources and is absorbable by the body. This technology has promising implications for treating various medical conditions, including pain management and cancer treatment.
Researchers have identified a key cause of metastasis from aggressive brain cancer in children and found a potential new therapy. Medulloblastoma cells hijack neurodevelopmental signaling pathways to promote tumor cell spreading. Targeting these pathways with a drug called dasatinib has shown promise in killing metastatic tumors.
Researchers discovered that quiescent ovarian cancer cells secrete follistatin, which induces resistance in neighboring cells and worsens survival rates. Targeting this protein may improve chemotherapy response and boost survival in patients with aggressive ovarian cancer.
Researchers have developed a microfluidic squeezing technology that stimulates anti-tumor activity in a subtype of HPV16-positive head and neck, cervical, and anal cancers. The treatment uses peripheral blood mononuclear cells trained to recognize and attack cancer cells without genetic modifications.
Researchers from Northwestern University discuss the multifaceted tumorigenic functions of EZH2, including its role in regulating translation and coactivating transcription. This new understanding may provide novel insights into advancing EZH2-targeting strategies for prostate cancer patients.
A new AI model developed at the University of British Columbia accurately predicts cancer patient survival using natural language processing to analyze oncologist notes. The model shows over 80% accuracy in predicting six-month, 36-month and 60-month survival rates.
Researchers discovered a new personalized immunotherapy combination that treats aggressive forms of advanced prostate cancer. By blocking PD-1-expressing macrophages and Wnt/β-catenin pathway activation, the therapy significantly improves response rates in PTEN-deficient cancers.